ActeaVentures is a global business development firm with operations in the US, Europe and Asia. We offer our clients comprehensive services covering all aspects of dealmaking and partnering in the Life Science industry.
Our team consists of Senior BD&L professionals with a long track record of successful dealmaking and partnering both as employees in Senior positions in big pharma (Pfizer, Lilly, Roche, Bayer/Schering), biotech (Cardion, Onyx Pharmaceuticals, PharmaMar, Amgen), diagnostics (Roche), as well as in independent consultancy roles.
ActeaVentures unifies all this expertise into a dynamic team which is eager to make your licensing project a lasting
success.
Take advantage of our skills and experience, our global presence, and our unrivaled industry network and contact us today for a preliminary discussion on how we may be able to assist you in achieving your partnering objectives.
Wednesday, 01 March 2023
Oncology Assets for Sale
ActeaVentures has been retained by an US-company for divesting/selling its bone-targeting oncology assets. The lead compound has demonstrated efficacy in a clinical pilot study in patients with bone metastases (results compare favorably to drug of market leader in this filed).
Another preclinical project targets osteosarcoma. The company's non-bone-targeting phosphate prodrug platform is available as well.
If interested, please contact us at info@acteaventures.com and we will provide you with a non-confidential slide deck.
Thursday, 09 February 2023
BioEurope Spring digital Basel, March 20-23, 2023